Perrigo Company plc Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
Perrigo Company plc (PRGO) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Percent of -7.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies · last filed 2026-02-26
- Perrigo Company plc effective income tax rate reconciliation, tax contingency, percent for fiscal 2025 was -7.30%.
- Perrigo Company plc effective income tax rate reconciliation, tax contingency, percent for fiscal 2017 was 25.30%.
- Perrigo Company plc effective income tax rate reconciliation, tax contingency, percent for fiscal 2016 was -0.80%.
- Perrigo Company plc effective income tax rate reconciliation, tax contingency, percent for fiscal 2015 was 17.70%, a 31.11% increase from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 6 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | -7.30% 10-K · filed 2026-02-26 | |||
| 2017-12-31 | 25.30% 10-K · filed 2018-03-01 | |||
| 2016-12-31 | -0.80% 10-K · filed 2018-03-01 | |||
| 2015-12-31 | 82.70% 10-K · filed 2018-03-01 | -10.10% 10-KT · filed 2016-02-25 | ||
| 2015-06-27 | 17.70% 10-K · filed 2018-03-01 | 18.50% 10-K · filed 2015-08-13 | ||
| 2014-06-28 | 13.50% 10-K · filed 2017-05-22 | 15.00% 10-K · filed 2014-08-14 | ||
| 2013-06-29 | 3.30% 10-KT · filed 2016-02-25 | |||
| 2012-06-30 | 3.90% 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |